A novel nanobody against urease activity of Helicobacter pylori

International Journal of Infectious Diseases

Volumn 17, Issue 9, 2013, Pages

  Ardekani, Leila Safaee ^a   Gargari, Seyed Latif Mousavi ^a   Rasooli, Iraj ^a   Bazl, Masoumeh Rajabi ^b   Mohammadi, Mohammad ^c   Ebrahimizadeh, Walead ^a   Bakherad, Hamid ^a   Zare, Hamed ^a  

^a SHAHED UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

Camelid; Heavy chain antibody; Helicobacter pylori; Nanobody; Phage display

Indexed keywords

NANOBODY; RECOMBINANT ENZYME; UREA; UREASE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIOPHAGE; CAMEL; CAMELUS DROMEDARIES; CROSS REACTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STABILITY; HELICOBACTER PYLORI; IMMUNE RESPONSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; THERMOSTABILITY; WESTERN BLOTTING;

CAMELID; HEAVY CHAIN ANTIBODY; HELICOBACTER PYLORI; NANOBODY; PHAGE DISPLAY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; CROSS REACTIONS; GENE LIBRARY; HELICOBACTER PYLORI; HUMANS; PROTEIN BINDING; PROTEIN STABILITY; PROTEOLYSIS; SINGLE-DOMAIN ANTIBODIES; TEMPERATURE; UREASE;

EID: 84881559062     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.02.015     Document Type: Article

References (40)

1. Petersen A.M., Krogfelt K.A. Helicobacter pylori: an invading microorganism? A review. FEMS Immunol Med Microbiol 2006, 36:117-126.
2. Sougioultzis S., Lee C.K., Alsahli M., Banerjee S., Cadoz M., Schrader R., et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002, 21:194-201.
3. Hatzifoti C., Bajaj-Elliott M., Dorrell N., Anyim M., Prentice M.B., Nye K.E., et al. A plasmid immunization construct encoding urease B of Helicobacter pylori induces an antigen-specific antibody response and upregulates the expression of β-defensins and IL-10 in the stomachs of immunized mice. Vaccine 2004, 22:2651-2659.
4. Ito Y., Shibata K., Hongo A., Kinoshita M. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol 1998, 345:193-198.
5. Lee M.H., Roussel Y., Wilks M., Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001, 19:3927-3935.
6. Izzotti A., Durando P., Ansaldi F., Gianiorio F., Pulliero A. Interaction between Helicobacter pylori, diet, and genetic polymorphisms as related to non-cancer diseases. Mutat Res 2009, 667:142-157.
7. Graham D.Y., Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008, 5:321-331.
8. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., El-Omar E., Graham D., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56:772-781.
9. Gisbert J., Gisbert J.L., Marcos S., Jimenez-Alonso I., Moreno-Otero R., Pajares J. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008, 27:346-354.
10. DeLoney C.R., Schiller N.L. Characterization of an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 2000, 44:3368-3373.
11. Trust T.J., Alm R.A., Pappo J. Helicobacter pylori: today's treatment, and possible future treatment. Eur J Surg 2003, 167:82-88.
12. Li H.X., Mao X.H., Shi Y., Ma Y., Wu Y.N., Zhang W.J., et al. Screening and identification of a novel B-cell neutralizing epitope from Helicobacter pylori UreB. Vaccine 2008, 26:6945-6949.
13. Houimel M., Mach J.P., Corthésy-Theulaz I., Corthesy B., Fisch I. New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. Eur J Biochem 2001, 262:774-780.
14. Rokita E., Makristathis A., Hirschl A.M., Rotter M.L. Purification of surface-associated urease from Helicobacter pylori. J Chromatogr B Biomed Sci Appl 2000, 737:203-212.
15. Malekshahi Z.V., Gargari S.L., Rasooli I., Ebrahimizadeh W. Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 2011, 51:366-372.
16. Hudson P.J., Souriau C. Engineered antibodies. Nat Med 2003, 9:129-134.
17. Berghman L., Abi-Ghanem D., Waghela S., Ricke S. Antibodies: an alternative for antibiotics?. Poult Sci 2005, 84:660-666.
18. Enever C., Batuwangala T., Plummer C., Sepp A. Next generation immunotherapeutics-honing the magic bullet. Curr Opin Biotechnol 2009, 20:405-411.
19. Chames P., Van Regenmortel M., Weiss E., Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009, 157:220-233.
20. Kuus-Reichel K., Grauer L., Karavodin L., Knott C., Krusemeier M., Kay N. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?. Clin Diagn Lab Immunol 1994, 1:365-372.
21. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hammers C., Songa E.B., et al. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
22. Kolkman J.A., Law D.A. Nanobodies-from llamas to therapeutic proteins. Drug Discov Today Technol 2010, 7:e139-e146.
23. Ebrahimizadeh W., Mousavi Gargari S., Rajabibazl M., Safaee Ardekani L., Zare H., Bakherad H. Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol 2012 Nov 8, [Epub ahead of print].
24. Spinelli S., Frenken L.G., Hermans P., Verrips T., Brown K., Tegoni M., et al. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 2000, 39:1217-1222.
25. HH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1999, 1431:37-46.
26. Alvarez-Rueda N., Ladjemi M.Z., Béhar G., Corgnac S., Pugnière M., Roquet F., et al. A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: immunogenicity and efficacy. Vaccine 2009, 27:4826-4833.
27. Lauwereys M., Ghahroudi M.A., Desmyter A., Kinne J., Hölzer W., De Genst E., et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998, 17:3512-3520.
28. Ikeda Y., Fujii R., Ogino K., Fukushima K., Hifumi E., Uda T. Immunological features and inhibitory effects on enzymatic activity of monoclonal antibodies against Helicobacter pylori urease. Journal of Fermentation and Bioengineering 1998, 86:271-276.
29. Nagata K., Mizuta T., Tonokatu Y., Fukuda Y., Okamura H., Hayashi T., et al. Monoclonal antibodies against the native urease of Helicobacter pylori: synergistic inhibition of urease activity by monoclonal antibody combinations. Infect Immun 1992, 60:4826-4831.
30. Wu Y., Zou Q., Luo P., Guo G., Wang X. Preparation of anti--{\sl Helicobacter pylori} UreB monoclonal antibody and the detection of the ability of inhibition the urease activity. Mian yi xue za zhi=Journal of Immunology 2005, 21:393.
31. Houimel M., Corthesy-Theulaz I., Fisch I., Wong C., Corthesy B., Mach J.P., et al. Selection of human single chain Fv antibody fragments binding and inhibiting Helicobacter pylori urease. Tumor Biol 2001, 22:36-44.
32. Reiche N., Jung A., Brabletz T., Vater T., Kirchner T., Faller G. Generation and characterization of human monoclonal scFv antibodies against Helicobacter pylori antigens. Infect Immun 2002, 70:4158-4164.
33. Van der Vaart J., Pant N., Wolvers D., Bezemer S., Hermans P., Bellamy K., et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 2006, 24:4130-4137.
34. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
35. Thys B., Schotte L., Muyldermans S., Wernery U., Hassanzadeh-Ghassabeh G., Rombaut B. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antivir Res 2010, 87:257-264.
36. Saerens D., Stijlemans B., Baral T.N., Nguyen Thi G.T., Wernery U., Magez S., et al. Parallel selection of multiple anti-infectome nanobodies without access to purified antigens. J Immunol Methods 2008, 329:138-150.
37. Arbabi Ghahroudi M., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997, 414:521-526.
38. Beatty J.D., Beatty B.G., Vlahos W.G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987, 100:173-179.
39. Tremblay J.M., Kuo C.L., Abeijon C., Sepulveda J., Oyler G., Hu X., et al. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 2010, 56:990-998.
40. Ahmadvand D., Rasaee M.J., Rahbarizadeh F., Kontermann R.E., Sheikholislami F. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol Immunol 2009, 46:1814-1823.